Validation study of age-independent fibrosis score (Fibrosis-3 index) in patients with metabolic dysfunction-associated steatotic liver disease

被引：3

作者：

Nouso, Kazuhiro ^{[1
,2
]}

Kawanaka, Miwa ^{[3
]}

Fujii, Hideki ^{[4
]}

Kariyama, Kazuya ^{[1
,2
]}

Toyoda, Hidenori ^{[5
]}

Iwaki, Michihiro ^{[6
]}

Hayashi, Hideki ^{[7
]}

Oeda, Satoshi ^{[8
,9
]}

Hyogo, Hideyuki ^{[10
]}

Morishita, Asahiro ^{[11
]}

Munekage, Kensuke ^{[12
,13
]}

Kawata, Kazuhito ^{[14
]}

Tsutsumi, Tsubasa ^{[15
]}

Sawada, Koji ^{[16
]}

Maeshiro, Tatsuji ^{[17
]}

Tobita, Hiroshi ^{[18
]}

Yoshida, Yuichi ^{[19
]}

Naito, Masafumi ^{[19
]}

Araki, Asuka ^{[20
]}

Arakaki, Shingo ^{[21
]}

Kawaguchi, Takumi ^{[15
]}

Noritake, Hidenao ^{[14
]}

Ono, Masafumi ^{[22
]}

Masaki, Tsutomu ^{[13
]}

Yasuda, Satoshi ^{[5
]}

Tomita, Eiichi ^{[7
]}

Yoneda, Masato ^{[6
]}

Tokushige, Akihiro ^{[23
]}

Kamada, Yoshihiro ^{[24
]}

Takahashi, Hirokazu ^{[25
]}

Ueda, Shinichiro ^{[25
]}

Aishima, Shinichi ^{[26
]}

Sumida, Yoshio ^{[27
]}

Nakajima, Atsushi ^{[7
]}

Kumada, Takashi ^{[5
,28
]}

Okanoue, Takeshi ^{[29
]}

机构：

[1] Okayama City Hosp, Dept Gastroenterol, Okayama, Japan

[2] Okayama City Hosp, Liver Dis Ctr, Okayama, Japan

[3] Kawasaki Med Sch, Gen Med Ctr, Dept Gen Internal Med 2, Okayama, Japan

[4] Osaka Metropolitan Univ, Grad Sch Med, Dept Hepatol, 1-4-3 Asahimachi,Abeno Ku, Osaka 5458585, Japan

[5] Ogaki Municipal Hosp, Dept Gastroenterol & Hepatol, Ogaki, Japan

[6] Yokohama City Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Yokohama, Kanagawa, Japan

[7] Gifu Municipal Hosp, Dept Gastroenterol & Hepatol, Gifu, Japan

[8] Saga Univ Hosp, Liver Ctr, Saga, Japan

[9] Saga Univ Hosp, Dept Lab Med, Saga, Japan

[10] Life Care Clin Hiroshima, Minami Ku, Hiroshima, Japan

[11] Kagawa Univ, Fac Med, Dept Gastroenterol & Neurol, Miki, Kagawa, Japan

[12] Kochi Med Sch, Dept Gastroenterol & Hepatol, Nankoku, Kochi, Japan

[13] Kochi Prefectural Hata Kenmin Hosp, Dept Gastroenterol, Sukumo, Japan

[14] Hamamatsu Univ, Dept Internal Med 2, Hepatol Div, Sch Med, Hamamatsu, Shizuoka, Japan

[15] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, Kurume, Fukuoka, Japan

[16] Asahikawa Med Univ, Dept Internal Med, Div Gastroenterol, Asahikawa, Hokkaido, Japan

[17] Urasoe Gen Hosp, Dept Gastroenterol, Urasoe, Japan

[18] Shimane Univ Hosp, Div Hepatol, Izumo, Shimane, Japan

[19] Suita Municipal Hosp, Dept Gastroenterol & Hepatol, Suita, Osaka, Japan

[20] Shimane Univ Hosp, Div Pathol, Izumo, Shimane, Japan

[21] Univ Ryukyus, Fac Med, Dept Internal Med 1, Nishihara, Okinawa, Japan

[22] Kagawa Univ, Fac Med, Div Innovat Med Hepatobiliary & Pancreatol, Miki, Kagawa, Japan

[23] Univ Ryukyus, Sch Med, Dept Clin Pharmacol & Therapeut, Nishihara, Okinawa, Japan

[24] Osaka Univ, Grad Sch Med, Dept Adv Metab Hepatol, Suita, Osaka, Japan

[25] Saga Univ Hosp, Liver Ctr, Saga, Japan

[26] Kyushu Univ, Dept Sci Pathol, Grad Sch Med Sci, Fukuoka, Japan

[27] Int Univ Healthcare & Welf, Grad Sch Healthcare Management, Minato Ku, Tokyo, Japan

[28] Gifu Kyoritsu Univ, Fac Nursing, Dept Nursing, Gifu, Japan

[29] Hepatol Ctr Saiseikai Suita Hosp, Suita, Osaka, Japan

来源：

HEPATOLOGY RESEARCH | 2024年 / 54卷 / 10期

关键词：

age; FIB-3; index; FIB-4; liver fibrosis; metabolic associated steatotic liver disease; TRANSIENT ELASTOGRAPHY; BIOPSY; FIB4;

D O I：

10.1111/hepr.14039

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background and Aims: Because the accuracy of the Fibrosis-4 (FIB-4) index for predicting liver fibrosis changes with age, the need for different cut-offs in various age groups has frequently been discussed. We developed the age-independent score, the Fibrosis-3 (FIB-3) index, and have shown its usefulness in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). This study aimed to validate the diagnostic ability of the FIB-3 index to predict fibrosis progression using a large new patient cohort. Methods: The ability of the FIB-3 index to predict liver fibrosis was analyzed by comparing it with that of the FIB-4 index using data from 1398 patients with MASLD enrolled in the Asia-based clinical outcome NAFLD study. Results: The areas under the receiver operating characteristic curves for predicting fibrosis stage F3 or higher were not different between the FIB-3 and FIB-4 indices in the entire cohort. Using the single ideal cut-offs of the indices (3.41 for FIB-3 index and 2.01 for FIB-4 index), the predictive accuracy of the FIB-3 index was not significantly different from that of the FIB-4 index among patients aged <60 years; however, the accuracy of the FIB-3 index was significantly higher than that of the FIB-4 index in those aged >= 60 years (0.645 and 0.529, respectively; p < 0.0001). Conclusion: The high ability of the FIB-3 index with a single cut-off to predict liver fibrosis in patients with MASLD was confirmed. The FIB-3 index could serve as a useful tool for assessing liver fibrosis regardless of age.

引用

页码：912 / 920

页数：9

共 50 条

[31] Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
Sotoudeheian, Mohammadjavad
PROTEIN AND PEPTIDE LETTERS, 2024, 31 (04) : 290 - 304
[32] Associations of five dietary indices with metabolic dysfunction-associated steatotic liver disease and liver fibrosis among the United States population
Xu, Min
Zhan, Yamei
Gao, Guohui
Zhu, Li
Wu, Tong
Xin, Guijie
FRONTIERS IN NUTRITION, 2024, 11
[33] Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk factors in rheumatoid arthritis
Saidi, A. N.
Theel, W. B.
Burggraaf, B.
van der Lelij, A. J.
Grobbee, D. E.
van Zeben, J. D.
van der Zwan-van Beek, E.
Rauh, S. P.
Cabezas, M. Castro
CLINICAL RHEUMATOLOGY, 2025, : 1485 - 1492
[34] Patterns of gastroenterology specialty referral for primary care patients with metabolic dysfunction-associated steatotic liver disease
Bobo, John F. G.
Keith, Brad A.
Marsden, Justin
Zhang, Jingwen
Schreiner, Andrew D.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2024, 368 (05) : 455 - 461
[35] The association between estimated glucose disposal rate and metabolic dysfunction-associated steatotic liver disease and liver fibrosis in US adults
Liu, Wanqian
Li, Xiaozhong
Chen, Ling
Luo, Xiao
BMC ENDOCRINE DISORDERS, 2025, 25 (01)
[36] Prediction of hepatic fibrosis using the aspartate transaminase-to-platelet ratio index in children and adolescents with metabolic dysfunction-associated steatotic liver disease
Jin, Hye Young
Noh, Eu Seon
Jeong, Hwalrim
Hwang, I. I. Tae
BMC PEDIATRICS, 2024, 24 (01)
[37] Associations between cardiometabolic indices and the onset of metabolic dysfunction-associated steatotic liver disease as well as its progression to liver fibrosis: a cohort study
Song, Ziping
Miao, Xinlei
Liu, Shuang
Hu, Manling
Xie, Xiaoling
Sun, Yuting
Leng, Song
CARDIOVASCULAR DIABETOLOGY, 2025, 24 (01) : 154
[38] Validation of Non-invasive Fibrosis Scores for Predicting Advanced Fibrosis in Metabolic-associated Fatty Liver Disease
Chen, Xiaoning
Goh, George Boon-Bee
Huang, Jiaofeng
Wu, Yinlian
Wang, Mingfang
Kumar, Rahul
Lin, Su
Zhu, Yueyong
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2022, 10 (04) : 589 - 594
[39] Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
Noureddin, Nabil
Copur-Dahi, Nedret
Loomba, Rohit
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 : S41 - S51
[40] EUS-guided shear wave elastography for fibrosis screening in patients with obesity and metabolic dysfunction-associated steatotic liver disease: a pilot study (with video)
Wang, Thomas J.
Jirapinyo, Pichamol
Shah, Raj
Schuster, Kimberly
Papke, David J.
Thompson, Christopher C.
Doyon, Laura
Lautz, David B.
Ryou, Marvin
GASTROINTESTINAL ENDOSCOPY, 2025, 101 (02) : 456 - 462.e1

← 1 2 3 4 5 →